KR20110010753A - 트레프로스티닐 일수화물 - Google Patents

트레프로스티닐 일수화물 Download PDF

Info

Publication number
KR20110010753A
KR20110010753A KR1020107027068A KR20107027068A KR20110010753A KR 20110010753 A KR20110010753 A KR 20110010753A KR 1020107027068 A KR1020107027068 A KR 1020107027068A KR 20107027068 A KR20107027068 A KR 20107027068A KR 20110010753 A KR20110010753 A KR 20110010753A
Authority
KR
South Korea
Prior art keywords
treprostinil
monohydrate
cancer
organic solvent
solid
Prior art date
Application number
KR1020107027068A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 월쉬
Original Assignee
유나이티드 세러퓨틱스 코오포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유나이티드 세러퓨틱스 코오포레이션 filed Critical 유나이티드 세러퓨틱스 코오포레이션
Publication of KR20110010753A publication Critical patent/KR20110010753A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes
KR1020107027068A 2008-05-08 2009-05-07 트레프로스티닐 일수화물 KR20110010753A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5150908P 2008-05-08 2008-05-08
US61/051,509 2008-05-08

Publications (1)

Publication Number Publication Date
KR20110010753A true KR20110010753A (ko) 2011-02-07

Family

ID=41037724

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027068A KR20110010753A (ko) 2008-05-08 2009-05-07 트레프로스티닐 일수화물

Country Status (8)

Country Link
US (1) US8350079B2 (de)
EP (2) EP2300408B1 (de)
JP (1) JP6219016B2 (de)
KR (1) KR20110010753A (de)
CN (1) CN102015613B (de)
CA (1) CA2723540C (de)
ES (1) ES2575565T3 (de)
WO (1) WO2009137066A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126908A (ko) * 2013-03-14 2015-11-13 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 고체 형태

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628654B2 (de) 2003-05-22 2019-12-04 United Therapeutics Corporation Verbindungen und verfahren zur abgabe von prostacyclin-analoga
EP2252570B1 (de) 2007-12-17 2017-04-05 United Therapeutics Corporation Verbessertes verfahren zur herstellung von treprostinil, dem wirkstoff in remodulin
ES2611187T3 (es) 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
JP6046034B2 (ja) 2010-06-03 2016-12-14 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの製造
US8461393B2 (en) 2011-03-02 2013-06-11 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193626B (zh) * 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) * 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US20140275616A1 (en) 2013-03-15 2014-09-18 United Therapeutics Corporation Salts of treprostinil
EP2978313B1 (de) 2013-03-25 2018-02-21 United Therapeutics Corporation Verfahren zur herstellung von prostacyclinverbindungen mit einem linker-thiol und pegylierten formen
WO2014179295A1 (en) 2013-04-30 2014-11-06 United Therapeutics Corporation Controlled release pharmaceutical formulations
WO2015061720A2 (en) 2013-10-25 2015-04-30 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
CN106573066A (zh) * 2014-06-13 2017-04-19 联合治疗学有限公司 曲前列环素制剂
WO2016038532A1 (en) * 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231186B1 (hu) 2014-10-08 2021-06-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás treprostinil és sói előállítására
EP3209415B1 (de) 2014-10-20 2020-02-19 United Therapeutics Corporation Synthese von zwischenprodukten zur herstellung von prostacyclinderivaten
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
IL310250A (en) 2016-05-05 2024-03-01 Liquidia Tech Inc Terfostinil in dry powder form for the treatment of pulmonary hypertension
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
KR20230119035A (ko) 2016-12-05 2023-08-14 코세어 파마 인코포레이티드 트레프로스티닐 및 이의 염의 피부 및 경피 투여
JP7194817B2 (ja) 2018-09-18 2022-12-22 イーライ リリー アンド カンパニー トレプロスチニルのエルブミン塩
WO2020223237A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
EP3981759A4 (de) * 2019-05-21 2023-07-19 Jiangsu Forefront Pharmaceutical Co., Ltd. Neue kristallform von treprostinil-natriumsalz und verfahren zu ihrer herstellung
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
US11339110B2 (en) 2019-12-19 2022-05-24 Chirogate International Inc. Efficient crystallization process for preparing ultrapure Treprostinil and crystal prepared therefrom
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
KR20230134480A (ko) 2020-12-14 2023-09-21 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
EP4301372A1 (de) 2021-03-03 2024-01-10 United Therapeutics Corporation Trockenpulverzusammensetzung aus trresteninil und seiner prodrug daraus sowie mit (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl)-2,5-diketopiperazin (fdkp)
US20230263807A1 (en) 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5763426A (en) * 1993-01-15 1998-06-09 Leo Pharmaceutical Products Ltd. Crystalline form of a vitamin D analogue
JP3215338B2 (ja) * 1995-12-15 2001-10-02 三菱化学株式会社 アミノベンゼンスルホン酸誘導体一水和物及びその製造方法
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
KR100638684B1 (ko) * 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
EP1628654B2 (de) 2003-05-22 2019-12-04 United Therapeutics Corporation Verbindungen und verfahren zur abgabe von prostacyclin-analoga
KR20050024121A (ko) * 2003-09-04 2005-03-10 동아제약주식회사 7-카르복시메틸옥시-3',4',5-트리메톡시 플라본.일수화물, 이의 제조방법 및 용도
CN1917883B (zh) * 2003-12-16 2011-05-11 联合治疗公司 曲前列环素在制备改善肾功能的药物中的用途
CN101647792B (zh) * 2003-12-16 2012-11-28 联合治疗公司 曲前列环素在制备治疗和预防缺血性损害的药物中的用途
US7879909B2 (en) 2004-04-12 2011-02-01 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
KR101390579B1 (ko) * 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2008118946A1 (en) 2007-03-27 2008-10-02 Atherogenics, Inc. Methods and compositions using certain phenolic derivatives for the treatment of diabetes
EP2252570B1 (de) * 2007-12-17 2017-04-05 United Therapeutics Corporation Verbessertes verfahren zur herstellung von treprostinil, dem wirkstoff in remodulin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126908A (ko) * 2013-03-14 2015-11-13 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 고체 형태

Also Published As

Publication number Publication date
CA2723540A1 (en) 2009-11-12
CN102015613B (zh) 2013-07-31
ES2575565T3 (es) 2016-06-29
EP2300408A1 (de) 2011-03-30
EP3002274A8 (de) 2016-07-13
JP2011519927A (ja) 2011-07-14
WO2009137066A1 (en) 2009-11-12
CA2723540C (en) 2016-01-05
EP2300408B1 (de) 2016-04-13
US20090281189A1 (en) 2009-11-12
JP6219016B2 (ja) 2017-10-25
CN102015613A (zh) 2011-04-13
EP3002274A1 (de) 2016-04-06
US8350079B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
KR20110010753A (ko) 트레프로스티닐 일수화물
TWI248938B (en) Macrolides
US9278903B2 (en) Crystal form of prostaglandin analogue, and preparation method and use thereof
US20090124814A1 (en) Process for preparing telmisartan
JP2024028794A (ja) オキサチアジン様化合物を作製する方法
JP2015508408A (ja) プロスタグランジン類似体の結晶型およびその製造方法と用途
EP2173732A2 (de) Herstellungsverfahren für docetaxel und polymorphe
CN105294585B (zh) 一种治疗痛风的化合物
BG64272B1 (bg) 'Ъ''АВИ, 'ЪДЪРЖА(tm)И ПРО'ИВОГЪБИ-НО 'Р...Д''ВО И А-...'А'...Н Б""...Р
WO2016095660A1 (zh) 头孢孟多酯钠化合物新晶型及其制剂和制备方法
CN112851666A (zh) 阿哌沙班与槲皮素共晶物及制备方法和其组合物与用途
CN103058972B (zh) 一类含环己烷结构的苯基c-葡萄糖苷衍生物、其制备方法和用途
CN100584835C (zh) 桂哌齐特的药用盐及其制备方法
JPH05163148A (ja) 抗腫瘍剤
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
JP6294665B2 (ja) スピロケタール誘導体の結晶
EP3984993A1 (de) Verwendung von aminothiolverbindungen als hirnnerven- oder herzschutzmittel
CN109134470B (zh) 一种含硒化合物及其用途
JPH0120A (ja) 臓器保護剤
EP2730575B1 (de) Kristalline form i eines salzes des dipeptidylpeptidase-iv-hemmers, verfahren zu ihrer herstellung und ihre verwendung
JP2019509325A (ja) Ｄｐｐｉｖ阻害剤のマレイン酸塩の多形およびその製造方法
CN117137913A (zh) 一种ARNi复合物与氨氯地平的复方药物组合物的新应用
CN117137921A (zh) 一种ARNi复合物的药物组合物的新应用
CN115490757A (zh) 活性氧自由基响应的多粘菌素前药化合物及其应用
CN102503954B (zh) 咪唑衍生物、其制备方法和用途

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150107

Effective date: 20150611